Quantcast
Last updated on April 20, 2014 at 14:04 EDT

Latest EYLEA Stories

2013-11-12 16:26:04

Detailed results from the Phase 3 VIBRANT trial of EYLEA in Macular Edema following Branch Retinal Vein Occlusion (BRVO) to be presented TARRYTOWN, N.Y., Nov. 12, 2013 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that data from several studies of EYLEA(®) (aflibercept) Injection will be presented during the annual meeting of the American Academy of Ophthalmology (AAO) to be held November 16-19 in New Orleans. EYLEA presentations will be featured during the...

2013-11-07 08:30:54

TARRYTOWN, N.Y., Nov. 7, 2013 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Bayer HealthCare today announced that Bayer HealthCare has submitted an application for marketing authorization in the European Union (EU) for EYLEA(®) (aflibercept) Injection for the treatment of patients with Diabetic Macular Edema (DME). Regeneron has submitted a supplemental BLA for EYLEA in this indication to the U.S. Food and Drug Administration (FDA). "Diabetes is a growing,...

Promising Results From Pilot Study For AMD
2013-06-18 13:40:01

University of Iowa There is no cure for age-related macular degeneration, an eye disease that is the leading cause of vision loss and blindness in older Americans. Last year, the National Institutes of Health reported that two drugs injected into the eyes, Avastin and Lucentis, eased symptoms for sufferers, especially those in the advanced, “wet” stage of the disease, when blood vessels in the eye become swollen and leak fluids in the eye. Yet for some AMD patients, the two...

2013-02-19 04:22:50

TARRYTOWN, N.Y. and BERLIN, Feb. 19, 2013 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Bayer HealthCare today announced that they have initiated a new Phase 3 trial (named VIVID EAST-DME) to evaluate the efficacy and safety of EYLEA(®) (aflibercept) Injection in the treatment of Diabetic Macular Edema (DME) in Russia, China, and other Asian countries. The companies are extending their global development program for EYLEA in DME after promising results in the global...

2012-12-06 04:23:31

TARRYTOWN, N.Y. and BERLIN, Dec. 6, 2012 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Bayer HealthCare today announced that Bayer HealthCare has submitted an application for marketing authorization in Europe for EYLEA (aflibercept) Injection for the treatment of macular edema following Central Retinal Vein Occlusion (CRVO). "It is our pleasure to announce the filing for EYLEA for the macular edema following CRVO indication with the European Regulatory Authority...

2012-11-27 04:20:35

TARRYTOWN, N.Y., Nov. 27, 2012 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that EYLEA(®) (aflibercept) Injection has been approved by the European Commission for the treatment of patients with neovascular (wet) age-related macular degeneration (wet AMD). According to the European Medicines Agency (EMA) approved Summary of Product Characteristics, EYLEA treatment is initiated with one 2 milligram (mg) injection per month for three consecutive months,...

2012-10-18 15:22:19

TARRYTOWN, N.Y., Oct. 18, 2012 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that detailed one-year results from the VIEW 1 and VIEW 2 Phase 3 studies of EYLEA (aflibercept) Injection were published online in the journal Ophthalmology ahead of a future print publication. The publication can be accessed at http://digitalreprints.elsevier.com/t/28599. "The article published today provides additional details about the VIEW 1 and VIEW 2 studies that demonstrated...

2011-11-21 17:07:00

In the news release, Regeneron Announces FDA Approval of EYLEA(TM) (aflibercept) Injection for the Treatment of Wet Age-Related Macular Degeneration, issued 18-Nov-2011 by Regeneron Pharmaceuticals, Inc. over PR Newswire, the third paragraph, second sentence, should read "EYLEA offers the potential of achieving the efficacy we've come to expect from current anti-VEGF agents, but with less frequent injections and monitoring." The complete, corrected release follows: Regeneron Announces FDA...

2011-11-18 17:42:00

TARRYTOWN, N.Y., Nov. 18, 2011 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced that the U.S. Food and Drug Administration (FDA) has approved EYLEA( )(aflibercept) Injection, known in the scientific literature as VEGF Trap-Eye, for the treatment of patients with neovascular (wet) Age-related Macular Degeneration (AMD) at a recommended dose of 2 milligrams (mg) every four weeks (monthly) for the first 12 weeks, followed by 2 mg every eight weeks (2...

2011-11-18 16:51:00

TARRYTOWN, N.Y., Nov. 18, 2011 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced that the U.S. Food and Drug Administration (FDA) has approved EYLEA( )(aflibercept) Injection, known in the scientific literature as VEGF Trap-Eye, for the treatment of patients with neovascular (wet) Age-related Macular Degeneration (AMD) at a recommended dose of 2 milligrams (mg) every four weeks (monthly) for the first 12 weeks, followed by 2 mg every eight weeks (2...